AMG 386 Drug-Drug Interaction Study With Paclitaxel

Phase 1CompletedNCT01992341

Amgen35 enrolled

Overview

The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel

Eligible subjects enrolled in the study will begin receiving paclitaxel on a three weeks on / one week off schedule at study day 1 and weekly AMG 386 beginning at study day 8. The pharmacokinetic portion of the study occurs during the first two study cycles with intensive PK collections on study weeks 1, 6 and 8. Once the pharmacokinetic assessment period is completed, continued combination therapy with AMG 386 and paclitaxel or single-agent AMG 386 will be administered at the investigator's discretion until progression, unacceptable toxicity develops, or study withdrawal.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Solid Tumors

Interventions

AMG 386DRUG

Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.

PaclitaxelDRUG

Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men or women ≥ 18 years of age * Have a pathologically documented, and definitely diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Normal or clinically acceptable ECG (12 lead reporting PR, QRS, QTc) Exclusion Criteria: * Subjects with gastric cancer or any malignancy with purely squamous cell histology * Known history of primary central nervous system (CNS) tumors or CNS metastases * Myocardial infarction within 1 year before study day 1, unstable or uncontrolled disease/condition related to or affecting cardiac function * History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study day 1 * A baseline ECG QTc interval \> 450 msec * Active grade 2 or greater peripheral vascular disease * History of pulmonary hemorrhage or gross hemoptysis within 6 months before study day 1 * Non-healing wound, ulcer (including gastrointestinal) or fracture * Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection * Major surgery within 1 month before study day 1 * Concurrent antitumor treatment within 4 weeks (6 weeks for nitrosoureas or mitomycin) before study day 1 * Unable to tolerate IV administration or repeated blood withdrawal * Hypersensitivity to paclitaxel or drugs using the vehicle cremophor * Known sensitivity to mammalian-derived products, bacterially-produced proteins, or any of the products to be administered during dosing * Chronic neuropathy grade ≥ 1 * Concurrent or prior treatment with 2C8 and 3A4 substrates * Enrolled in or has not yet completed at least 30 days (prior to study day 1) since ending other investigational device or drug, or currently receiving other investigational treatment. * Men and woman of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and an additional 6 months after the last dose of AMG 386 * Women who are lactating/breastfeeding * Women with a positive pregnancy test * Women planning to become pregnant during the duration of the study

Locations (2)

University of Colorado Cancer Center

Aurora, Colorado, United States

University of Utah Huntsman Cancer Institute

Salt Lake City, Utah, United States

Outcomes

Primary Outcomes

Paclitaxel PK parameters

Paclitaxel PK parameters with and without the co-administration of AMG 386.

Time frame: 9 weeks

Secondary Outcomes

AMG 386 PK parameters

AMG 386 PK steady state PK parameters with and without paclitaxel co-administration

Time frame: 9 weeks

Safety

Subject incidence of treatment-emergent adverse events: Assessments include physical examinations, vitals, clinical laboratories, and electrocardiograms (ECG) • Results of safety laboratory tests, vital sign measurements, and ECG measurments

Time frame: Average of 6 months

Safety

Incidence of anti-AMG 386 antibody formation

Time frame: Average of 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.